Do not share your Ozempic® pen with other people, even if the needle has been changed. You may give other people a serious infection or get a serious infection from them.
Terms and conditions of use
NovoCare® Pharmacy (CoAssist Pharmacy d/b/a NovoCare® Pharmacy)
Covered products:
Wegovy® (semaglutide) injection 2.4 mg
Total strength per total volumeNDC
0.25 mg/0.5 mL
0169-4525-14
0.5 mg/0.5 mL
0169-4505-14
1 mg/0.5 mL
0169-4501-14
1.7 mg/0.75 mL
0169-4517-14
2.4 mg/0.75 mL
0169-4524-14
Wegovy® (semaglutide) tablets 25 mg
Total strength per tabletNDC
1.5 mg tablets
00169-4415-31
4 mg tablets
00169-4404-31
9 mg tablets
00169-4409-31
25 mg tablets
00169-4425-31
Wegovy® HD (semaglutide) injection 7.2 mg
Total strength per total volumeNDC
7.2 mg/0.5 mL
0169-4572-14
Ozempic® (semaglutide) injection 0.5 mg, 1 mg, 2 mg
Total strength per total volumeNDC
2 mg/3 mL
0169-4181-13
4 mg/3 mL
0169-4130-13
8 mg/3 mL
0169-4772-12
Eligibility and Restrictions
Ozempic®:
To participate in the Ozempic® NovoCare® Pharmacy program, patients must have a valid prescription for Ozempic®. A valid Prescriber ID# is required on the prescription.
Patients are not eligible for the Ozempic® NovoCare® Pharmacy program if enrolled in any federal or state health care program with prescription drug coverage, such as Medicaid, Medicare, Medigap, VA, DOD, TRICARE, or any similar federal or state health care program (each a government program), or where prohibited by law.
Patients may only participate in this NovoCare® program for Ozempic® if they have been prescribed Ozempic® for an FDA-approved indication within that product’s labeling.
Wegovy®:
In order to participate in the Wegovy® NovoCare® Pharmacy program, patient must have a valid prescription for Wegovy®. A valid Prescriber ID# is required on the prescription.
Patients must either be uninsured or have insurance but decide to self-pay. Patients may only participate in this Wegovy® program if they have been prescribed Wegovy® for an FDA-approved indication with that product’s labeling.
Program Details for Ozempic®
By using this program, the patient must certify that he/she meets the eligibility criteria and will comply with the terms and conditions described for Ozempic® Eligibility, Ozempic®’s Program Details, and Program Details applicable to either Ozempic® or Wegovy®.
Patient agrees they will not seek reimbursement or otherwise submit a claim to any insurer for any medication received through this program.
When a prescription for Ozempic® is received from a licensed prescriber, NovoCare® will review and validate the prescription. Patients will have the option to utilize the self-pay/cash program through CenterWell® and/or CoAssist Pharmacy d/b/a NovoCare® Pharmacy (“NovoCare® Pharmacy”), or, for those who have commercial insurance, have NovoCare® Pharmacy transfer the prescription to a retail pharmacy to apply their commercial prescription insurance to the prescription fulfillment.
The table below explains what patients can pay based on which medicine they receive:
Ozempic® (semaglutide) injection 0.5 mg, 1 mg, 2 mg
Ozempic® Injection Self-pay offer details
NDC
Description
Limited Time Offera patient price
The Limited Time Offer patient price is available to New Patients (as defined below) who meet the Limited Time Offer requirements. This offer applies to a maximum of the first two (2) 28‑day fills during the applicable offer period. Any third fill will be priced at the Standard Offer*** patient price.
1-monthb
2-monthb
3-monthb
00169-4181-13
Ozempic® - 0.25 mg or 0.5 mg doses, 1 pen - 3mL
$199.00
NA
NA
NDC
Description
Standard Offerc patient price
1-monthb
2-monthb
3-monthb
00169-4181-13
Ozempic® - 0.25 mg or 0.5 mg doses, 1 pen - 3mL
$349.00
$698.00
$1,047.00
00169-4130-13
Ozempic® - 1 mg doses, 1 pen
$349.00
$698.00
$1,047.00
00169-4772-12
Ozempic® - 2 mg doses, 1 pen
$499.00
$998.00
$1,497.00
Limited Time Offera patient price
The Limited Time Offer patient price is available to New Patients (as defined below) who meet the Limited Time Offer requirements. This offer applies to a maximum of the first two (2) 28‑day fills during the applicable offer period. Any third fill will be priced at the Standard Offer*** patient price.
NDC
00169-4181-13
Description
Ozempic® - 0.25 mg or 0.5 mg doses, 1 pen - 3mL
| 1-monthb | 2-monthsb | 3-monthsb |
| $199.00 | NA | NA |
Standard Offerc Patient Price
NDC
00169-4181-13
Description
Ozempic® - 0.25 mg or 0.5 mg doses, 1 pen - 3mL
| 1-monthb | 2-monthsb | 3-monthsb |
| $349.00 | $698.00 | $1,047.00 |
NDC
00169-4130-13
Description
Ozempic® - 1 mg doses, 1 pen
| 1-monthb | 2-monthsb | 3-monthsb |
| $349.00 | $698.00 | $1,047.00 |
NDC
00169-4772-12
Description
Ozempic® - 2 mg doses, 1 pen
| 1-monthb | 2-monthsb | 3-monthsb |
| $499.00 | $998.00 | $1,497.00 |
aLimited Time Offer Requirements:
New Patients are eligible patients who have never filled a Ozempic® Injection prescription through NovoCare® Pharmacy.
For Ozempic® Injection- Eligible patients may use this Limited Time Offer if the prescription is written on or before 6/30/26, received by the pharmacy by the end of day on 6/30/26, and shipped on or before 7/30/26. The Limited Time Offer applies to the first two (2) 28‑day fills. The third fill will be priced at the Standard Offerc price
bFor Ozempic® Injection, a "1-Month" fill shall refer to 1 box of 1 Ozempic® Pen equivalent to a 28-Day Supply, “2-Month” fill shall refer to 2 boxes of 1 Ozempic® Pen equivalent to a 56-Day Supply, and a “3-Month” fill shall refer to 3 boxes of 1 Ozempic® Pen equivalent to a 84-Day Supply.
cStandard Offer:
Standard offer pricing applies to patients who are not eligible for the Limited Time Offer.
Wegovy® Program Details
By using this program, patient must certify that he/she meets the eligibility criteria and will comply with the terms and conditions described for Wegovy® Eligibility, Wegovy®’s Program Details, and Program Details applicable to either Wegovy® or Ozempic®.
Patient also agrees that they will not seek reimbursement for any medication received through this program.
When a prescription for Wegovy® is received from a licensed prescriber, NovoCare® will review and validate the prescription. Patients will have the option to utilize the self-pay/cash program through CenterWell® and/or CoAssist Pharmacy d/b/a NovoCare® Pharmacy (“NovoCare® Pharmacy”).
Patients in this Wegovy® self-pay program who otherwise might participate in Medicare Part D or a Medicare Advantage prescription drug plan must agree to the following conditions for the Wegovy® self-pay/NovoCare® Pharmacy program:
- The patient must agree not to seek reimbursement from their Medicare Part D or Medicare Advantage prescription plan for their out-of-pocket costs for their Wegovy® prescription or count the costs of their prescription toward their deductible or True out-of-pocket (“TrOOP”) costs.
- The patient must also agree to purchase all of their Wegovy® prescriptions through the program for the entire calendar year.
- The patient must agree to permit Novo Nordisk to notify the patient’s Medicare Part D or Medicare Advantage prescription plan about their participation in the program.
The table below explain what patients enrolled in the program can pay based on which medicine they receive:
Wegovy® (semaglutide) injection 2.4 mg, 7.2 mg:
Wegovy® Injectable Self-pay offer details
NDC
Description
Limited Time Offerd patient price
The Limited Time Offer patient price is available to new patients (as defined below) who meet the Limited Time Offer requirements. This offer applies to a maximum of the first two (2) 28‑day fills during the applicable offer period. Any third fill will be priced at the Standard Offere patient price.
1-monthf
2-monthf
3-monthf
00169-4525-14
Wegovy® - 0.25 mg 4 Single-Dose Prefilled Pens
$199.00
NA
NA
00169-4505-14
Wegovy® - 0.5 mg 4 Single-Dose Prefilled Pens
$199.00
NA
NA
Wegovy® Injectable
NDC
Description
Standard Offere patient price
1-monthf
2-monthf
3-monthf
00169-4525-14
Wegovy® - 0.25 mg 4 Single-Dose Prefilled Pens
$349.00
$698.00
$1,047.00
00169-4505-14
Wegovy® - 0.5 mg 4 Single-Dose Prefilled Pens
$349.00
$698.00
$1,047.00
00169-4501-14
Wegovy® - 1.0 mg 4 Single-Dose Prefilled Pens
$349.00
$698.00
$1,047.00
00169-4517-14
Wegovy® - 1.7 mg 4 Single-Dose Prefilled Pens
$349.00
$698.00
$1,047.00
00169-4524-14
Wegovy® - 2.4 mg 4 Single-Dose Prefilled Pens
$349.00
$698.00
$1,047.00
00169-4572-14
Wegovy® HD - 7.2 mg 4 Single-Dose Prefilled Pens
$399.00
$798.00
$1,197.00
Limited Time Offerd patient price
The Limited Time Offer patient price is available to new patients (as defined below) who meet the Limited Time Offer requirements. This offer applies to a maximum of the first two (2) 28‑day fills during the applicable offer period. Any third fill will be priced at the Standard Offere patient price.
NDC
00169-4525-14
Description
Wegovy® - 0.25 mg 4 Single-Dose Prefilled Pens
| 1-monthf | 2-monthsf | 3-monthsf |
| $199.00 | NA | NA |
NDC
00169-4505-14
Description
Wegovy® - 0.5 mg 4 Single-Dose Prefilled Pens
| 1-monthf | 2-monthsf | 3-monthsf |
| $199.00 | NA | NA |
Wegovy® Injectable
Standard Offerc Patient Price
NDC
00169-4525-14
Description
Wegovy® - 0.25 mg 4 Single-Dose Prefilled Pens
| 1-monthf | 2-monthsf | 3-monthsf |
| $349.00 | $698.00 | $1,047.00 |
NDC
00169-4505-14
Description
Wegovy® - 0.5 mg 4 Single-Dose Prefilled Pens
| 1-monthf | 2-monthsf | 3-monthsf |
| $349.00 | $698.00 | $1,047.00 |
NDC
00169-4501-14
Description
Wegovy® - 1.0 mg 4 Single-Dose Prefilled Pens
| 1-monthf | 2-monthsf | 3-monthsf |
| $349.00 | $698.00 | $1,047.00 |
NDC
00169-4517-14
Description
Wegovy® - 1.7 mg 4 Single-Dose Prefilled Pens
| 1-monthf | 2-monthsf | 3-monthsf |
| $349.00 | $698.00 | $1,047.00 |
NDC
00169-4524-14
Description
Wegovy® - 2.4 mg 4 Single-Dose Prefilled Pens
| 1-monthf | 2-monthsf | 3-monthsf |
| $349.00 | $698.00 | $1,047.00 |
NDC
00169-4572-14
Description
Wegovy® HD - 7.2 mg 4 Single-Dose Prefilled Pens
| 1-monthf | 2-monthsf | 3-monthsf |
| $399.00 | $798.00 | $1,197.00 |
dLimited Time Offer Requirements:
New Patients are eligible patients who have never filled a Wegovy® Injection prescription through NovoCare® Pharmacy.
For Wegovy® Injection- Eligible patients may use this Limited Time Offer if the prescription is written on or before 6/30/26, received by the pharmacy by the end of day on 6/30/26, and shipped on or before 7/30/26. The Limited Time Offer applies to the first two (2) 28‑day fills. The third fill will be priced at the Standard Offerb price
eStandard Offer:
Standard offer pricing applies to patients who are not eligible for the Limited Time Offer.
fFor Wegovy® Injection, a “1-Month” fill shall refer to 1 box of 4 Single-Dose Prefilled Pens equivalent to a 28-Day Supply, “2-Month” fill shall refer to 2 boxes of 4 Single-Dose Prefilled Pens equivalent to a 56-Day Supply, and a “3-Month” fill shall refer to 3 boxes of 4 Single-Dose Prefilled Pens equivalent to a 84-Day Supply.
Wegovy® (semaglutide) tablets 25 mg:
Wegovy® Tablets Self-pay offer details
NDC
Description
Limited Time Offerg patient price
1-monthh
2-monthh
3-monthh
00169-4404-31
Wegovy® 4 mg 30 tablets Bottle
$149.00
NA
NA
NDC
Description
Standard Offeri patient price
1-monthh
2-monthh
3-monthh
00169-4415-31
Wegovy® 1.5 mg 30 tablets Bottle
$149.00
$298.00
$447.00
00169-4404-31
Wegovy® 4 mg 30 tablets Bottle
$199.00
$398.00
$597.00
00169-4409-31
Wegovy® 9 mg 30 tablets Bottle
$299.00
$598.00
$897.00
00169-4425-31
Wegovy® 25 mg 30 tablets Bottle
$299.00
$598.00
$897.00
Limited Time Offerg patient price
NDC
00169-4404-31
Description
Wegovy® 4 mg 30 tablets Bottle
| 1-monthh | 2-monthsh | 3-monthsh |
| $149.00 | NA | NA |
Standard Offeri Patient Price
NDC
00169-4415-31
Description
Wegovy® 1.5 mg 30 tablets Bottle
| 1-monthh | 2-monthsh | 3-monthsh |
| $149.00 | $298.00 | $447.00 |
NDC
00169-4404-31
Description
Wegovy® 4 mg 30 tablets Bottle
| 1-monthh | 2-monthsh | 3-monthsh |
| $199.00 | $398.00 | $597.00 |
NDC
00169-4409-31
Description
Wegovy® 9 mg 30 tablets Bottle
| 1-monthh | 2-monthsh | 3-monthsh |
| $299.00 | $598.00 | $897.00 |
NDC
00169-4425-31
Description
Wegovy® 25 mg 30 tablets Bottle
| 1-monthh | 2-monthsh | 3-monthsh |
| $299.00 | $598.00 | $897.00 |
gLimited Time Offer Requirements:
New Patients are eligible patients who have never filled a Wegovy® Injection prescription through NovoCare® Pharmacy.
For Wegovy® tablets, eligible patients may use this Limited Time Offer if the prescription is written on or before 8/31/26, received by the pharmacy by the end of day on 8/31/26, and shipped on or before 9/30/26.
hFor Wegovy® tablets, a “1-Month” fill shall refer to 1 bottle of 30 tablets equivalent to a 30-Day Supply, a “2-Month” fill shall refer to 2 bottles of 30 tablets equivalent to a 60-Day Supply, and a “3-Month” fill shall refer to 3 bottles of 30 tablets equivalent to a 90-Day Supply. For the sake of clarity, Pharmacy will only dispense increments of 30 tablets.
iStandard Offer:
Standard offer pricing applies to patients who are not eligible for the Limited Time Offer.
Program Details that Apply to Wegovy® or Ozempic®
NovoCare® Pharmacy operates through licensed pharmacies that dispense product under a cash-pay model, and insurance is not accepted. These cash prescriptions are filled by CenterWell® Pharmacy or CoAssist Pharmacy d/b/a Novocare® Pharmacy.
Novo Nordisk’s Eligibility and Restrictions, and Program Details, may change from time to time, and for the most recent version, please visit this webpage. Reconfirmation of patient information may be requested periodically to ensure accuracy of data and compliance with terms. Patients with questions about the program may call 1-888-809-3942.
This offer is not insurance. This offer is not contingent on any past, current, or future purchase of Ozempic® or Wegovy®. This offer cannot be combined with any other coupon, free trial, discount, prescription savings card, or other offer not associated with this offer. This offer is valid only in the United States and its territories, unless prohibited by law.
Assurance of Medication Supply
This program will continue to enroll patients so long as each enrolled patient can receive a consistent supply of medication. This assurance is only applicable for those patients who remain enrolled and adherent to the treatment. Novo Nordisk reserves the right to pause or terminate enrollment to prioritize supply for those qualified.
Disclosure of Third-Party Partnerships
AssistRx: A patient solutions provider responsible for NovoCare®’s access and reimbursement live support program. They manage patient intake and outreach and offer live support.
CoAssist: A licensed pharmacy in all 50 US states and territories that, for purposes of this program, is CoAssist Pharmacy d/b/a NovoCare® Pharmacy. CoAssist takes in the prescription after NovoCare®’s access and reimbursement live support program reviews the patient’s insurance type and benefits investigation to determine eligibility for the program. Eligible patients may then have their HCP’s prescription transferred from CoAssist to CenterWell® Pharmacy, where CenterWell® further validates the prescription, and processes it for shipment to the patient’s home, or CoAssist Pharmacy d/b/a NovoCare® Pharmacy may act as the dispensing pharmacy.
CenterWell®: NovoCare®’s dispensing pharmacy responsible for patient accounts, payment collection, medication fulfillment, tracking, and shipping.